SCHEMBL5223004

SCHEMBL5223004

CNC(=O)c1cccnc1N1CCN(Cc2ccc(-c3ccc(-c4noc(C)n4)cc3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.47
PLK1 P53350 1/20 0.47
CHIA Q9BZP6 1/20 0.42
P2RX3 P56373 1/20 0.42
TSHR P16473 3/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KCNH2 Q12809 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
DRD2 P14416 1/20 0.41
HTR2A P28223 1/20 0.41
DRD3 P35462 1/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5312395 0.81 ALDH1A1 (0.45) P2RX3TSHRLMNAALDH1A1MAPT
SCHEMBL5221962 0.80 ALDH1A1 (0.63) TSHRLMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL5225628 0.76 ALDH1A1 (0.58) TSHRLMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL5223016 0.74 TSHR (0.47) PLK1P2RX3TSHRLMNAALDH1A1
SCHEMBL5225958 0.72 SMN1; SMN2 (0.59) TSHRLMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL7070548 0.72 MGLL (0.56) TSHRLMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL5928148 0.72 ALDH1A1 (0.47) TSHRLMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL5225149 0.71 SMN1; SMN2 (0.61) TSHRLMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL5223197 0.71 SMN1; SMN2 (0.53) TSHRLMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL5224880 0.70 SMN1; SMN2 (0.62) TSHRLMNAALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP claimed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO claimed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US claimed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019998-A1 Histamine-3 receptor antagonist HRH3, HRH4, HRH2 EPHX2 838/4885PLK1 1208/4885CHIA 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.